Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
330
Million yen (improvement in net loss for the period)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending August 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-1,473 million
Ordinary income-1,452 Million yen net loss before income taxes
Net income¥-1,455 million
Selling, general and administrative expenses318 Million yen other general and administrative expenses
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Research and development and information disclosure progressed broadly as planned, but no business partnership was realized.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decrease in R&D expenses-¥270 million
- Decrease in rogocekib research and development expenses-¥272 million
- Increase in U.S. CRO costs+¥248 million
- Decrease in drug substance and drug product-related costs-¥521 million
- Decrease in other general and administrative expenses-¥46 million
- Increase in non-operating income and extraordinary gainsUp ¥32 million year on year
- Increase in non-operating expenses and extraordinary losses+¥18 million
New initiatives
- Fundraising through the 12th series of stock acquisition rights to complete the rogocekib expansion cohort, conduct the DDI study, and prepare for the start of the Phase 2 clinical trial
- Preparation for an international joint clinical trial, including Japan, using AMED's "GRiT" program
- Pursuit of domestic and international business partnerships focused on rogocekib
- Improving fixed-cost efficiency and concentrating management resources on rogocekib
Key KPIsA metric the company considers important as a management benchmark.
- Total clinical trial enrollment129 People
- Enrollment in Japan60 Engagements
- Enrollment in the United States70 Engagements
- Patients in the dose-escalation cohorts of the U.S. Phase 1/2 trial42 cases
- IE cohort enrollment27 cases
- Overall response rate (U.S. trial)11.8 %
- Overall response rate (Japanese Phase 1 trial)42.9 %
Number of employees
Number of Employees22 People
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending August 2026 |
| Operating profit | ¥-1,473 million |
| Ordinary income | -1,452 Million yen (net loss before income taxes) |
| Net income | ¥-1,455 million |
| Selling, general and administrative expenses | 318 Million yen (other general and administrative expenses) |
| Self-assessment against the plan | Research and development and information disclosure progressed broadly as planned, but no business partnership was realized. |
| Breakdown of Factors Affecting the Change | Factors Decrease in R&D expenses / Amount -¥270 million, Factors Decrease in rogocekib research and development expenses / Amount -¥272 million, Factors Increase in U.S. CRO costs / Amount +¥248 million, Factors Decrease in drug substance and drug product-related costs / Amount -¥521 million, Factors Decrease in other general and administrative expenses / Amount -¥46 million, Factors Increase in non-operating income and extraordinary gains / Amount Up ¥32 million year on year, Factors Increase in non-operating expenses and extraordinary losses / Amount +¥18 million |
| Key KPIs | Indicator name Total clinical trial enrollment / Value 129 People / Year on year against the same period last year Not disclosed, Indicator name Enrollment in Japan / Value 60 Engagements / Year on year against the same period last year Not disclosed, Indicator name Enrollment in the United States / Value 70 Engagements / Year on year against the same period last year Not disclosed, Indicator name Patients in the dose-escalation cohorts of the U.S. Phase 1/2 trial / Value 42 cases / Year on year against the same period last year Not disclosed, Indicator name IE cohort enrollment / Value 27 cases / Year on year against the same period last year Not disclosed, Indicator name Overall response rate (U.S. trial) / Value 11.8 % / Year on year against the same period last year Not disclosed, Indicator name Overall response rate (Japanese Phase 1 trial) / Value 42.9 % / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 22 People / Changes during the period and hiring plan Not disclosed |
| New initiatives | Fundraising through the 12th series of stock acquisition rights to complete the rogocekib expansion cohort, conduct the DDI study, and prepare for the start of the Phase 2 clinical trial, Preparation for an international joint clinical trial, including Japan, using AMED's "GRiT" program, Pursuit of domestic and international business partnerships focused on rogocekib, Improving fixed-cost efficiency and concentrating management resources on rogocekib |
Items this document does not state (20)
Net SalesGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses decreased because, although U.S. CRO costs increased, manufacturing-related costs during the period were limited as a certain amount of drug substance and drug product for clinical trials had already been secured. General and administrative expenses decreased due to the impact of the pro forma standard taxation associated with the capital reduction, patent-related costs, and fixed-cost reduction measures.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.